Tegaderm

Tegaderm is a medical dressing and wound-care brand whose best-known products are transparent film dressings designed to cover and protect wounds, intravenous catheter sites, vascular-access devices, and other areas requiring a visible protective barrier. The brand originated within 3M Health Care and, following the April 1, 2024 separation of 3M’s Health Care business, is now part of Solventum Corporation’s medical-surgical portfolio. Because the separation is relatively recent, many products continue to carry the combined “3M Tegaderm” designation while Solventum gradually updates packaging and commercial materials. The core Tegaderm concept is a thin, transparent adhesive film that conforms to the body while allowing clinicians and patients to observe the covered site without removing the dressing. Depending on the product, the film may be waterproof, breathable, sterile, hypoallergenic, latex-free, or configured with a reinforced border and application frame. These characteristics support use in hospitals, outpatient care, first aid, home care, infusion therapy, and device securement. The products are generally positioned as protective and securement solutions rather than as substitutes for clinical treatment of infection or serious injury. Tegaderm’s portfolio extends beyond basic transparent film. It includes frame-style and border-style dressings for wounds and vascular-access sites; specialized high-holding-power and diamond-pattern films for humid or challenging conditions; antimicrobial intravenous dressings incorporating chlorhexidine gluconate; port dressings and gel pads for implanted venous-access devices; advanced IV securement dressings; silicone foam and silicone-border foam dressings; hydrogel wound fillers; superabsorber dressings; and silver alginate wound dressings. This range allows the brand to serve both routine dressing needs and more specialized clinical applications. In professional healthcare, Tegaderm is particularly associated with intravenous therapy and catheter-site management. Transparent construction supports continuous visual assessment, while antimicrobial variants are designed to reduce microbial colonization and the risk of catheter-related bloodstream infection when used according to their labeling and clinical protocols. The Tegaderm CHG line combines a transparent dressing with chlorhexidine gluconate protection, and related products are designed for peripheral IVs, midline catheters, central venous catheters, PICCs, dialysis catheters, arterial catheters, epidural catheters, implanted ports, and other percutaneous devices. The brand also has recognizable consumer and first-aid uses. Retail-oriented transparent dressings can protect minor cuts, scrapes, burns, blisters, and abrasions while allowing the covered area to remain visible. The film’s flexibility and conformability have also led to informal uses such as securing finger buddy straps and protecting newly applied tattoos, although medical instructions and product indications remain the authoritative guide for use. The name Tegaderm combines roots associated with covering and skin: “tega,” from Latin for cover, and “derm,” from Greek for skin. Its market identity has therefore remained closely tied to transparent protection, breathability, visibility, and reliable adhesion. Historically marketed under 3M, the brand’s current corporate context is Solventum, an independent publicly traded healthcare company created through the 2024 spin-off. Solventum has stated that product packaging will transition from the 3M name to the Solventum name by March 31, 2028, without an intended change to the products themselves. Tegaderm is consequently an active legacy healthcare brand in the middle of a corporate identity transition rather than a discontinued 3M product line.

Tegaderm is a medical dressing brand associated with the development and commercialization of transparent adhesive films for protecting wounds and securing medical devices. The available reference material does not establish a precise founding year or identify an individual founder, so the brand’s origin is best described through its product function and corporate lineage rather than through a specific launch date. The brand’s central innovation is the transparent film dressing. Unlike an opaque gauze covering, the film allows the underlying wound or catheter site to remain visible. This visibility is important in clinical settings because it permits inspection for drainage, inflammation, dislodgement, or other changes without automatically removing the dressing. The film is also designed to conform to the contours of the body, including areas that move frequently or have irregular surfaces. Product literature describes breathability, flexibility, waterproof protection, and adhesion as important elements of the Tegaderm proposition. Over time, Tegaderm developed from a recognizable transparent-film product into a broader dressing platform. Basic frame-style and border-style films were joined by products for intravenous catheter securement, advanced IV applications, and challenging moisture conditions. High-holding-power and specialized pattern-coated films were introduced for circumstances in which ordinary adhesion may be less reliable. The brand also expanded into products using different wound-care technologies, including silicone foam, hydrogel, superabsorber, alginate, and silver alginate formats. These products serve different levels of exudate management, skin protection, cushioning, and antimicrobial care. A major part of Tegaderm’s professional identity is its use in IV and catheter-site management. The brand’s antimicrobial portfolio includes products incorporating chlorhexidine gluconate, commonly abbreviated CHG. Tegaderm CHG products combine transparent site visibility with antimicrobial protection and catheter securement. Depending on the product, they are intended for peripheral IVs, midline catheters, central venous catheters, PICCs, dialysis catheters, arterial catheters, epidural catheters, implanted venous ports, and related percutaneous devices. Product labeling includes important age and safety restrictions, demonstrating that the brand operates within regulated medical-device frameworks rather than as an unrestricted consumer adhesive. Tegaderm has also acquired a secondary presence in first aid and home care. Retail transparent dressings can be used over minor cuts, scrapes, burns, blisters, and abrasions. The clear material supports visual monitoring, while the flexible film is intended to remain in place during normal movement and, for designated products, bathing or water exposure. Informal uses such as protecting tattoos and supporting finger buddy-strapping have contributed to the brand’s broader public recognition, although clinical indications and instructions for use take priority over informal practice. For most of its history, Tegaderm was identified with 3M. The brand was part of 3M Health Care, alongside a large portfolio of medical, dental, surgical, and health-information products. The most important corporate turning point in its recent history came on April 1, 2024, when 3M completed the planned spin-off of its Health Care business as Solventum Corporation. The transaction made Solventum an independent public company listed on the New York Stock Exchange under the ticker SOLV. Tegaderm therefore changed corporate ownership context without becoming a discontinued brand. Solventum has continued to sell Tegaderm products and has maintained the 3M Tegaderm naming convention during the transition. Its rebranding guidance states that packaging across the former 3M Health Care portfolio is expected to move to the Solventum name by March 31, 2028, with no intended change to the products customers use. Current product pages show both the continuing Tegaderm trademark and the new Solventum corporate environment. The brand’s present identity is consequently dual-layered: Tegaderm remains the product-facing medical brand, while Solventum is the current corporate owner and operating healthcare company. Today, Tegaderm occupies a broad position across wound care, first aid, infusion therapy, catheter securement, and advanced medical dressings. Its enduring differentiators are transparency, site visibility, conformability, breathable barrier performance, and specialized securement or antimicrobial features. The precise product assortment varies by market and regulatory jurisdiction, but the brand remains active and commercially relevant within Solventum’s medical-surgical business.

1. 2025Continued antimicrobial and advanced dressing development

   Solventum continued to list Tegaderm CHG, antimicrobial transparent, advanced IV securement, silicone foam, hydrogel, superabsorber, and silver alginate offerings across its medical dressing portfolio.

   Source
2. 20243M Health Care becomes Solventum

   3M completed the spin-off of its Health Care business on April 1, 2024. Tegaderm became part of the newly independent Solventum healthcare company.

   Source
3. Development of the transparent film dressing platform

   Tegaderm became identified with transparent adhesive film dressings used to cover wounds and protect catheter sites while maintaining visibility of the underlying area. A precise development year is not established in the available source material.

   Source
4. Expansion into IV-site and catheter securement

   The brand expanded beyond general wound coverage into transparent dressings and securement products for peripheral IVs, central lines, PICCs, implanted ports, and other percutaneous devices.

   Source
5. Scheduled completion of packaging transition

   Solventum states that packaging for products from the former 3M Health Care portfolio is planned to transition to the Solventum name by March 31, 2028, without an intended change to the products.

   Source

A clinically oriented medical dressing platform centered on transparent protection, wound visibility, breathable barriers, IV-site securement, and antimicrobial catheter care. The brand serves institutional healthcare, professional wound care, infusion therapy, first aid, and selected consumer applications.

• Tegaderm Transparent Film DressingTransparent film dressing

  The core Tegaderm format is a thin transparent film dressing used to cover and protect wounds, catheter sites, and other areas requiring a visible barrier. Depending on the specific catalog number, it may be sterile, waterproof, latex-free, or supplied in frame-style formats that support consistent application. The film is intended to permit observation of the covered site while helping block external contaminants and maintain a favorable wound environment.

• Tegaderm Transparent Film Dressing with BorderBordered transparent film dressing

  Bordered versions add a reinforced adhesive perimeter to the transparent film. They are used for wound coverage and for securing medical devices to the skin. The border is intended to improve handling and help resist edge lift while preserving visual access to the wound or insertion site. Specific designs and indications differ by market and product number.

• Tegaderm CHG Chlorhexidine Gluconate I.V. Securement DressingAntimicrobial IV securement dressing

  This professional IV product combines a transparent dressing, catheter securement features, and a chlorhexidine gluconate gel pad. It is designed for several types of vascular and percutaneous catheters, including peripheral IVs, midlines, central venous catheters, PICCs, dialysis catheters, arterial catheters, and epidural catheters. The transparent construction supports continuous inspection, while the CHG component provides antimicrobial protection within the labeled use period.

• Tegaderm CHG Chlorhexidine Gluconate I.V. Port DressingImplanted-port dressing

  The CHG I.V. Port Dressing is intended for implanted venous ports and non-coring Huber needles, including applications in oncology and hematology. It combines a transparent CHG gel pad with a cover dressing and an adhesive design intended to reduce interference with the needle during removal. The transparent components permit inspection of the port area, while securement strips support tubing and dressing stabilization.

• Tegaderm Antimicrobial Transparent Dressing 9124Antimicrobial peripheral IV dressing

  The 9124 product is a peripheral IV dressing in which chlorhexidine gluconate is formulated into the dressing adhesive. Its integrated construction combines antimicrobial protection with site visibility, breathability, and IV securement. It is part of the brand’s effort to provide products tailored to peripheral vascular-access care rather than relying solely on a separate gel pad.

• Tegaderm I.V. Advanced Securement DressingAdvanced IV securement dressing

  The advanced securement family is designed to stabilize IV catheters while maintaining a clear view of the insertion site. Product designs may include conforming borders, patterned adhesives, securement strips, and application features intended to improve consistency and reduce movement or edge lift. The portfolio includes products for peripheral IV and other vascular-access applications.

• Tegaderm Silicone Foam DressingSilicone foam wound dressing

  Tegaderm silicone foam products are intended for wound management where cushioning, exudate handling, and gentle interaction with the skin are important. Silicone adhesive technology is positioned for use on fragile or sensitive skin and is designed to permit removal with less trauma than some conventional adhesives. Product shapes and absorbency characteristics vary by model.

• Tegaderm Hydrogel Wound FillerHydrogel wound-care product

  The hydrogel wound filler line is designed for wound-care situations in which moisture donation or maintenance may be clinically useful. It forms part of the brand’s advanced wound-care portfolio rather than its basic transparent-film range. Use, dressing changes, and suitability depend on wound condition and the product’s instructions for use.

• Tegaderm Superabsorber DressingSuperabsorber wound dressing

  Superabsorber dressings are intended for wounds producing substantial exudate. Their role is to manage and retain wound fluid while helping protect surrounding skin and reduce the frequency of dressing disruption when clinically appropriate. The product is part of the broader advanced wound-care range marketed under the Tegaderm name.

• Tegaderm Alginate AG Silver DressingSilver alginate antimicrobial wound dressing

  The alginate AG silver range combines an alginate dressing format with silver-based antimicrobial technology. It is intended for selected wound-care applications requiring exudate management and antimicrobial properties. The product is distinct from the transparent film family and demonstrates the brand’s expansion into advanced wound-care materials.

• 2025Expansion and continued maintenance of antimicrobial Tegaderm offeringsProduct launch

  Catheter-related infection prevention and reliable vascular-access securement remain important needs in hospital and infusion settings.

  What changed. Solventum continued to market Tegaderm CHG securement dressings, CHG port dressings, antimicrobial transparent dressings, and advanced IV securement products for different catheter and access-site applications.

  Aftermath. The brand’s professional positioning increasingly emphasizes an integrated combination of visibility, securement, breathability, and antimicrobial protection rather than transparent film alone.

  Source
• 2024Transfer of Tegaderm into the independent Solventum healthcare companyM&A

  Tegaderm had been part of 3M Health Care. 3M announced and completed a planned separation of that business into Solventum Corporation, changing the brand’s corporate parent and public-market context.

  What changed. On April 1, 2024, 3M distributed 80.1% of Solventum’s outstanding shares to 3M stockholders and ceased consolidating the Health Care business. Tegaderm continued as a product brand within the separated healthcare portfolio.

  Aftermath. Solventum became an independent public company trading under SOLV. Tegaderm product pages continued to use the 3M Tegaderm name during the transition, while Solventum assumed responsibility for the business and future branding.

  Source
• 2024Planned transition from 3M packaging to Solventum packagingStrategy

  The new Solventum organization needed to establish an independent corporate identity while preserving continuity for products inherited from 3M Health Care.

  What changed. Solventum announced a phased packaging and branding transition. Products, including Tegaderm offerings, are expected to move from 3M-branded packaging to Solventum-branded packaging by March 31, 2028.

  Aftermath. The Tegaderm trademark and product identity remain in use, but customers may encounter both legacy 3M Tegaderm and emerging Solventum Tegaderm materials during the transition period. Solventum states that the packaging change is not intended to alter the products themselves.

  Source

• 2026Solventum appoints Neil Zieselman as controller and chief accounting officer

  Solventum announced the appointment of Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026.

  Leadership change
  Source
• 2025Solventum continues commercial development of Tegaderm CHG products

  Solventum continued to market Tegaderm CHG and related antimicrobial IV securement products for catheter and implanted-port applications, including products using chlorhexidine gluconate in a gel pad or adhesive formulation.

  Product generationOther
  Source
• 2025FDA premarket notification lists Tegaderm Post-Op Transparent Antimicrobial Dressing

  An FDA 510(k) record identified Solventum US, LLC as the submitter for a Tegaderm Post-Op Transparent Antimicrobial Dressing premarket notification received in June 2025.

  RegulationProduct launch
  Source
• 2025Solventum names Heather Knight Chief Commercial Officer

  Solventum appointed Heather Knight as Chief Commercial Officer, consolidating oversight of global commercial and research-and-development operations across its major healthcare segments, including the medical-surgical activities associated with Tegaderm.

  Leadership change
  Source
• 20243M completes spin-off of its Health Care business into Solventum

  On April 1, 2024, 3M completed the separation of its Health Care business into Solventum Corporation. Tegaderm moved into the portfolio of the newly independent healthcare company, while 3M retained a minority ownership interest at the time of the transaction.

  M&AOther
  Source
• 2024Solventum begins transition from 3M-branded packaging

  Solventum announced that products from the former 3M Health Care portfolio would progressively transition to Solventum-branded packaging, with the packaging change scheduled to be completed by March 31, 2028. The company stated that the transition would not change the products themselves.

  Other
  Source

1. Tegaderm
2. Tegaderm Medical
3. 3M Tegaderm CHG Chlorhexidine Gluconate I.V. Securement Dressing
4. 3M Tegaderm CHG Chlorhexidine Gluconate I.V. Port Dressing
5. 3M Tegaderm Antimicrobial Transparent Dressing 9124
6. 3M Tegaderm Silicone Border Foam Dressing
7. Rebranding from 3M to Solventum
8. 3M Completes Spin-off of Solventum
9. Solventum Leadership
10. Solventum 2025 Form 10-K
11. Solventum appoints Neil Zieselman as controller and chief accounting officer
12. FDA premarket notification lists Tegaderm Post-Op Transparent Antimicrobial Dressing
13. Solventum names Heather Knight Chief Commercial Officer